(Q37247578)

19 August 2017

1 reference

title

Molecular mechanisms of L-DOPA-induced dyskinesia (English)

1 reference

19 August 2017

1 reference

Peter Jenner

1

1 reference

PubMed ID

18714325

19 August 2017

language of work or name

English

0 references

publication date

1 September 2008

1 reference

Nature Reviews Neuroscience

19 August 2017

1 reference

19 August 2017

9

1 reference

19 August 2017

9

1 reference

19 August 2017

665-677

1 reference

https://scigraph.springernature.com/pub.10.1038/nrn2471

19 August 2017

0 references

cites work

Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity

1 reference

Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030.

31 March 2020

1 reference

Medical management of levodopa-associated motor complications in patients with Parkinson's disease

31 March 2020

1 reference

Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature

31 March 2020

1 reference

Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations

31 March 2020

1 reference

How common are complications of Parkinson's disease?

31 March 2020

1 reference

Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study

31 March 2020

1 reference

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

31 March 2020

1 reference

Circuits and circuit disorders of the basal ganglia

31 March 2020

1 reference

Pathophysiology of the basal ganglia in Parkinson's disease.

31 March 2020

1 reference

Neural mechanisms in disorders of movement.

31 March 2020

1 reference

A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment

31 March 2020

1 reference

Functional anatomy of movement disorders

31 March 2020

1 reference

D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons

31 March 2020

1 reference

Consequence of nigrostriatal denervation and L-dopa therapy on the expression of glutamic acid decarboxylase messenger RNA in the pallidum

31 March 2020

1 reference

Metabolic activity of the basal ganglia in parkinsonian syndromes in human and non-human primates: a cytochrome oxidase histochemistry study.

31 March 2020

1 reference

Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and nonhuman primates: an in situ hybridization study of cytochrome oxidase subunit I mRNA

31 March 2020

1 reference

The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits.

31 March 2020

1 reference

Single-axon tracing study of neurons of the external segment of the globus pallidus in primate

31 March 2020

1 reference

Unilateral and bilateral pallidotomy for idiopathic Parkinson's disease: a case series of 115 patients.

31 March 2020

1 reference

Dopamine replacement therapy does not restore the full spectrum of normal pallidal activity in the 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine primate model of Parkinsonism.

31 March 2020

1 reference

Reduction in subthalamic 8-35 Hz oscillatory activity correlates with clinical improvement in Parkinson's disease.

31 March 2020

1 reference

Late emergence of synchronized oscillatory activity in the pallidum during progressive Parkinsonism.

31 March 2020

1 reference

Competition between feedback loops underlies normal and pathological dynamics in the basal ganglia.

31 March 2020

1 reference

Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys

31 March 2020

1 reference

Is levodopa toxic to human substantia nigra?

31 March 2020

1 reference

Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases

31 March 2020

1 reference

Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding.

31 March 2020

1 reference

Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

31 March 2020

1 reference

Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).

31 March 2020

1 reference

Young onset Parkinson's disease

31 March 2020

1 reference

A comparison of clinical and pathological features of young- and old-onset Parkinson's disease

31 March 2020

1 reference

Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model

31 March 2020

1 reference

Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning.

31 March 2020

1 reference

Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage

31 March 2020

1 reference

Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms

31 March 2020

1 reference

New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity

31 March 2020

1 reference

Dyskinesias in normal squirrel monkeys induced by nomifensine and levodopa

31 March 2020

1 reference

Levodopa induces dyskinesias in normal squirrel monkeys

31 March 2020

1 reference

L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations

31 March 2020

1 reference

Levodopa in the treatment of Parkinson's disease: current controversies

31 March 2020

1 reference

Clinical pharmacokinetics of anti-parkinsonian drugs

31 March 2020

1 reference

Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients

31 March 2020

1 reference

Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease

31 March 2020

1 reference

Pharmacodynamics of levodopa in Parkinson's disease

31 March 2020

1 reference

Peripheral pharmacokinetic parameters of levodopa/carbidopa and the on-off phenomenon in parkinsonian patients

31 March 2020

1 reference

The Yin and Yang of dopamine release: a new perspective

31 March 2020

1 reference

The tonic/phasic model of dopamine system regulation: its relevance for understanding how stimulant abuse can alter basal ganglia function

31 March 2020

1 reference

Levodopa motor complications in Parkinson's disease

31 March 2020

1 reference

Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease

31 March 2020

1 reference

Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications

31 March 2020

1 reference

Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?

31 March 2020

1 reference

Development of dyskinesias in a 5-year trial of ropinirole andL-dopa

31 March 2020

1 reference

Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates

31 March 2020

1 reference

Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates

31 March 2020

1 reference

Intermittent vs Continuous Levodopa Administration in Patients With Advanced Parkinson Disease

31 March 2020

1 reference

Impact of pramipexole on the onset of levodopa-related dyskinesias

31 March 2020

1 reference

Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa

31 March 2020

1 reference

Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys

31 March 2020

1 reference

Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets

31 March 2020

1 reference

Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates

31 March 2020

1 reference

Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys

31 March 2020

1 reference

Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.

31 March 2020

1 reference

Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease

31 March 2020

1 reference

Chronic high-frequency stimulation of the subthalamic nucleus and L-DOPA treatment in experimental parkinsonism: effects on motor behaviour and striatal glutamate transmission.

31 March 2020

1 reference

Deep-brain stimulation in Parkinson's disease: long-term efficacy and safety - What happened this year?

31 March 2020

1 reference

Surgical therapy for Parkinson's disease

31 March 2020

1 reference

What has been learnt from study of dopamine receptors in Parkinson's disease?

31 March 2020

1 reference

Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.

31 March 2020

1 reference

Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.

31 March 2020

1 reference

Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates.

31 March 2020

1 reference

Receptor-activity modifying protein 1 expression is increased in the striatum following repeated L-DOPA administration in a 6-hydroxydopamine lesioned rat model of Parkinson's disease.

31 March 2020

1 reference

L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain

31 March 2020

1 reference

Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease.

31 March 2020

1 reference

Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa

31 March 2020

1 reference

Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function

31 March 2020

1 reference

D3 receptor expression within the basal ganglia is not affected by Parkinson's disease

31 March 2020

1 reference

Dopamine D3 receptors in the basal ganglia of the common marmoset and following MPTP and L-DOPA treatment.

31 March 2020

1 reference

Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets.

31 March 2020

1 reference

Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA

31 March 2020

1 reference

Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease

31 March 2020

1 reference

Consequences of nigrostriatal denervation on the gamma-aminobutyric acidic neurons of substantia nigra pars reticulata and superior colliculus in parkinsonian syndromes

31 March 2020

1 reference

Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease

31 March 2020

1 reference

Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease

31 March 2020

1 reference

ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice

31 March 2020

1 reference

Expression pattern of JunD after acute or chronic L-DOPA treatment: comparison with deltaFosB.

31 March 2020

1 reference

Persistent changes in striatal gene expression induced by long-term L-DOPA treatment in a rat model of Parkinson's disease

31 March 2020

1 reference

Effect of levodopa chronic administration on behavioral changes and fos expression in basal ganglia in rat model of PD

31 March 2020

1 reference

Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex

31 March 2020

1 reference

Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys: effects on basal ganglia GABA(A)/benzodiazepine receptor complex and GABA content.

31 March 2020

1 reference

Levodopa response motor complications--GABA receptors and preproenkephalin expression in human brain

31 March 2020

1 reference

Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications

31 March 2020

1 reference

Normalization of GABAA receptor specific binding in the substantia nigra reticulata and the prevention of L-dopa-induced dyskinesias in MPTP parkinsonian monkeys

31 March 2020

1 reference

GABA(A) and mu-opioid receptor binding in the globus pallidus and endopeduncular nucleus of animals symptomatic for and recovered from experimental Parkinsonism

31 March 2020

1 reference

Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia.

31 March 2020

1 reference

PET studies and motor complications in Parkinson's disease

31 March 2020

1 reference

Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys

31 March 2020

1 reference

Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias

31 March 2020

1 reference

Opiate receptor avidity is reduced in non-motor impaired MPTP-lesioned rhesus monkeys.

31 March 2020

1 reference

Opiate receptor avidity is reduced bilaterally in rhesus monkeys unilaterally lesioned with MPTP.

31 March 2020

1 reference

Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia

31 March 2020

1 reference

Alterations in opiate receptor binding in MPTP-induced hemiparkinsonian monkeys

31 March 2020

1 reference

Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias

31 March 2020

1 reference

Industry forum: Progress in pursuit of therapeutic A2A antagonists: The adenosine A2A receptor selective antagonist KW6002: Research and development toward a novel nondopaminergic therapy for Parkinson's disease

31 March 2020

1 reference

Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications

31 March 2020

1 reference

Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys

31 March 2020

1 reference

Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease

31 March 2020

1 reference

Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure

31 March 2020

1 reference

Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease

31 March 2020

1 reference

Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

31 March 2020

1 reference

Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia

31 March 2020

1 reference

Pathological synaptic plasticity in the striatum: implications for Parkinson's disease.

31 March 2020

1 reference

Dopamine-mediated regulation of corticostriatal synaptic plasticity.

31 March 2020

1 reference

l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation

31 March 2020

1 reference

D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons

31 March 2020

1 reference

Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys

31 March 2020

1 reference

Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors

31 March 2020

1 reference

Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin

31 March 2020

1 reference

Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease

31 March 2020

1 reference

The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.

31 March 2020

1 reference

Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys

31 March 2020

1 reference

Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease

31 March 2020

1 reference

Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD.

31 March 2020

1 reference

AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys

31 March 2020

1 reference

Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease

31 March 2020

1 reference

Striatal plasticity and extrapyramidal motor dysfunction

31 March 2020

1 reference

Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets

31 March 2020

1 reference

Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration.

31 March 2020

1 reference

Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits.

31 March 2020

1 reference

Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease

31 March 2020

1 reference

Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism

31 March 2020

1 reference

Striatal glutamatergic mechanisms and extrapyramidal movement disorders

31 March 2020

1 reference

Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

31 March 2020

1 reference

Cyclic AMP responsive element binding protein phosphorylation and persistent expression of levodopa-induced response alterations in unilateral nigrostriatal 6-OHDA lesioned rats.

31 March 2020

1 reference

Striatal histone modifications in models of levodopa-induced dyskinesia

31 March 2020

1 reference

A critical role of the nitric oxide/cGMP pathway in corticostriatal long-term depression.

31 March 2020

1 reference

Phasic dopaminergic transmission increases NO efflux in the rat dorsal striatum via a neuronal NOS and a dopamine D(1/5) receptor-dependent mechanism

31 March 2020

1 reference

Unraveling substantia nigra sequential gene expression in a progressive MPTP-lesioned macaque model of Parkinson's disease

31 March 2020

1 reference

Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes

31 March 2020

1 reference

Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia

31 March 2020

1 reference

Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70.

31 March 2020

1 reference

Normalization and expression changes in predefined sets of proteins using 2D gel electrophoresis: a proteomic study of L-DOPA induced dyskinesia in an animal model of Parkinson's disease using DIGE

31 March 2020

1 reference

Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia

31 March 2020

1 reference

Morphological changes in the rat neostriatum after unilateral 6-hydroxydopamine injections into the nigrostriatal pathway.

31 March 2020

1 reference

Plasticity of synapses in the rat neostriatum after unilateral lesion of the nigrostriatal dopaminergic pathway.

31 March 2020

1 reference

Atrophy of medium spiny I striatal dendrites in advanced Parkinson's disease

31 March 2020

1 reference

Evidence of a breakdown of corticostriatal connections in Parkinson's disease.

31 March 2020

1 reference

Striatal plasticity in parkinsonism: dystrophic changes in medium spiny neurons and progression in Parkinson's disease.

31 March 2020

1 reference

Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models.

31 March 2020

1 reference

A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia

31 March 2020

1 reference

Is L-dopa an endogenous neurotransmitter?

31 March 2020

1 reference

Deep brain stimulation for the treatment of Parkinson's disease.

31 March 2020

1 reference

Randomized trial of pallidotomy versus medical therapy for Parkinson's disease

31 March 2020

1 reference

Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations

31 March 2020

1 reference

Use of apomorphine in Parkinson's disease.

31 March 2020

1 reference

Timing of treatment initiation in Parkinson's disease: a need for reappraisal?

31 March 2020

1 reference

Clinical trials with rasagiline: evidence for short-term and long-term effects

31 March 2020

1 reference

GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets

31 March 2020

1 reference

Glial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosets

31 March 2020

1 reference

The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration

31 March 2020

1 reference

Animal models of neurological deficits: how relevant is the rat?

31 March 2020

1 reference

Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model.

31 March 2020

1 reference

Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.

31 March 2020

1 reference

Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.

31 March 2020

1 reference

Levodopa-induced dyskinesias

31 March 2020

1 reference

Nondopaminergic mechanisms in levodopa-induced dyskinesia

31 March 2020

1 reference

The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications

31 March 2020

1 reference

Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors.

31 March 2020

1 reference

The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1

31 March 2020

1 reference

The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease

31 March 2020

1 reference

Coadministration of (-)-OSU6162 with l-DOPA normalizes preproenkephalin mRNA expression in the sensorimotor striatum of primates with unilateral 6-OHDA lesions

31 March 2020

1 reference

Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy.

31 March 2020

1 reference

Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis.

31 March 2020

1 reference

The neuropathological effects of antipsychotic drugs

31 March 2020

1 reference

Regional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatment

31 March 2020

1 reference

Effect of haloperidol and clozapine on the density of "perforated" synapses in caudate, nucleus accumbens, and medial prefrontal cortex

31 March 2020

1 reference

Correlation of vacuous chewing movements with morphological changes in rats following 1-year treatment with haloperidol

31 March 2020

1 reference

Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum

31 March 2020

1 reference

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRN2471

1 reference

release_unzzvdpdyva7ddvvy37kd7xjmy

19 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/unzzvdpdyva7ddvvy37kd7xjmy

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

18714325

1 reference

PubMed ID

18714325